<VariationArchive VariationID="202191" VariationName="NM_000404.4(GLB1):c.1577dup (p.Trp527fs)" VariationType="Duplication" Accession="VCV000202191" Version="36" RecordType="classified" NumberOfSubmissions="8" NumberOfSubmitters="8" DateLastUpdated="2024-07-29" DateCreated="2015-07-03" MostRecentSubmission="2024-07-15">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="198618" VariationID="202191">
      <GeneList>
        <Gene Symbol="GLB1" FullName="galactosidase beta 1" GeneID="2720" HGNC_ID="HGNC:4298" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>3p22.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="3" Accession="NC_000003.12" start="32961108" stop="33097146" display_start="32961108" display_stop="33097146" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="3" Accession="NC_000003.11" start="33038099" stop="33138693" display_start="33038099" display_stop="33138693" Strand="-" />
          </Location>
          <OMIM>611458</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_000404.4(GLB1):c.1577dup (p.Trp527fs)</Name>
      <CanonicalSPDI>NC_000003.12:33014212:CCCCCC:CCCCCCC</CanonicalSPDI>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>3p22.3</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="3" Accession="NC_000003.12" start="33014212" stop="33014213" display_start="33014212" display_stop="33014213" variantLength="1" positionVCF="33014212" referenceAlleleVCF="G" alternateAlleleVCF="GC" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="3" Accession="NC_000003.11" start="33055704" stop="33055705" display_start="33055704" display_stop="33055705" variantLength="1" positionVCF="33055704" referenceAlleleVCF="G" alternateAlleleVCF="GC" />
      </Location>
      <OtherNameList>
        <Name>1622_1627insG</Name>
      </OtherNameList>
      <ProteinChange>W527fs</ProteinChange>
      <ProteinChange>W575fs</ProteinChange>
      <ProteinChange>W497fs</ProteinChange>
      <ProteinChange>W396fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000003.11" sequenceAccession="NC_000003" sequenceVersion="11" change="g.33055710dup" Assembly="GRCh37">
            <Expression>NC_000003.11:g.33055710dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000003.12" sequenceAccession="NC_000003" sequenceVersion="12" change="g.33014218dup" Assembly="GRCh38">
            <Expression>NC_000003.12:g.33014218dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_009005.1" sequenceAccession="NG_009005" sequenceVersion="1" change="g.87990dup">
            <Expression>NG_009005.1:g.87990dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000404.4" sequenceAccession="NM_000404" sequenceVersion="4" change="c.1577dup" MANESelect="true">
            <Expression>NM_000404.4:c.1577dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000395.3" sequenceAccession="NP_000395" sequenceVersion="3" change="p.Trp527fs">
            <Expression>NP_000395.3:p.Trp527fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001079811.3" sequenceAccession="NM_001079811" sequenceVersion="3" change="c.1487dup">
            <Expression>NM_001079811.3:c.1487dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001073279.2" sequenceAccession="NP_001073279" sequenceVersion="2" change="p.Trp497fs">
            <Expression>NP_001073279.2:p.Trp497fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001135602.3" sequenceAccession="NM_001135602" sequenceVersion="3" change="c.1184dup">
            <Expression>NM_001135602.3:c.1184dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001129074.2" sequenceAccession="NP_001129074" sequenceVersion="2" change="p.Trp396fs">
            <Expression>NP_001129074.2:p.Trp396fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001317040.2" sequenceAccession="NM_001317040" sequenceVersion="2" change="c.1721dup">
            <Expression>NM_001317040.2:c.1721dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001303969.2" sequenceAccession="NP_001303969" sequenceVersion="2" change="p.Trp575fs">
            <Expression>NP_001303969.2:p.Trp575fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001393580.1" sequenceAccession="NM_001393580" sequenceVersion="1" change="c.1577dup">
            <Expression>NM_001393580.1:c.1577dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001380509.1" sequenceAccession="NP_001380509" sequenceVersion="1" change="p.Trp527fs">
            <Expression>NP_001380509.1:p.Trp527fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000404.2" sequenceAccession="NM_000404" sequenceVersion="2" change="c.1577dupG">
            <Expression>NM_000404.2:c.1577dupG</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000404.4" sequenceAccession="NM_000404" sequenceVersion="4" change="c.1577dupG" MANESelect="true">
            <Expression>NM_000404.4:c.1577dupG</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef ID="CA203855" DB="ClinGen" />
        <XRef Type="rs" ID="794729217" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000404.4(GLB1):c.1577dup (p.Trp527fs) AND Infantile GM1 gangliosidosis" Accession="RCV000184037" Version="5">
        <ClassifiedConditionList TraitSetID="244">
          <ClassifiedCondition DB="MedGen" ID="C0268271">Infantile GM1 gangliosidosis</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no classification provided</ReviewStatus>
            <Description SubmissionCount="1">not provided</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000404.4(GLB1):c.1577dup (p.Trp527fs) AND not provided" Accession="RCV000627406" Version="20">
        <ClassifiedConditionList TraitSetID="9460">
          <ClassifiedCondition DB="MedGen" ID="C3661900">not provided</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2018-06-01" SubmissionCount="2">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000404.4(GLB1):c.1577dup (p.Trp527fs) AND multiple conditions" Accession="RCV000798976" Version="4">
        <ClassifiedConditionList TraitSetID="10013">
          <ClassifiedCondition DB="MedGen" ID="C0085131">GM1 gangliosidosis</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0086652">Mucopolysaccharidosis, MPS-IV-B</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-12-30" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000404.4(GLB1):c.1577dup (p.Trp527fs) AND GM1 gangliosidosis type 2" Accession="RCV000987139" Version="2">
        <ClassifiedConditionList TraitSetID="245">
          <ClassifiedCondition DB="MedGen" ID="C0268272">GM1 gangliosidosis type 2</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2019-05-28" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000404.4(GLB1):c.1577dup (p.Trp527fs) AND GM1 gangliosidosis" Accession="RCV001260322" Version="2">
        <ClassifiedConditionList TraitSetID="11702">
          <ClassifiedCondition DB="MedGen" ID="C0085131">GM1 gangliosidosis</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2020-09-17" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000404.4(GLB1):c.1577dup (p.Trp527fs) AND GM1 gangliosidosis type 3" Accession="RCV003137707" Version="2">
        <ClassifiedConditionList TraitSetID="246">
          <ClassifiedCondition DB="MedGen" ID="C0268273">GM1 gangliosidosis type 3</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2022-10-17" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000404.4(GLB1):c.1577dup (p.Trp527fs) AND GLB1-related disorder" Accession="RCV004528961" Version="1">
        <ClassifiedConditionList TraitSetID="84661">
          <ClassifiedCondition DB="MedGen" ID="CN377807">GLB1-related disorder</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2019-01-01" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2023-12-30" NumberOfSubmissions="8" NumberOfSubmitters="8" DateCreated="2015-07-03" MostRecentSubmission="2024-07-15">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">10338095</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">15986423</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">16941474</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">17309651</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">18524657</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">21637542</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">25936995</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">31761138</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="84661" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="67627" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">GLB1-related disorder</ElementValue>
              </Name>
              <XRef ID="CN377807" DB="MedGen" />
            </Trait>
          </TraitSet>
          <TraitSet ID="11702" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="7352" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">GM1 gangliosidosis</ElementValue>
                <XRef ID="MONDO:0018149" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Beta galactosidase 1 deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">GLB 1 deficiency</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="10891" />
                <XRef ID="10891" DB="Office of Rare Diseases" />
              </AttributeSet>
              <XRef ID="354" DB="Orphanet" />
              <XRef ID="C0085131" DB="MedGen" />
              <XRef ID="MONDO:0018149" DB="MONDO" />
            </Trait>
          </TraitSet>
          <TraitSet ID="244" Type="Disease" ContributesToAggregateClassification="false">
            <Trait ID="5204" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Infantile GM1 gangliosidosis</ElementValue>
                <XRef ID="238026007" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">GM1-gangliosidosis, type I</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gangliosidosis, generalized GM1, infantile form</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">GLB1 deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">GM1 gangliosidosis type 1</ElementValue>
                <XRef ID="MONDO:0009260" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gangliosidosis, Generalized GM1, Type 1</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">GLB1-related disorders comprise two phenotypically distinct lysosomal storage disorders: GM1 gangliosidosis and mucopolysaccharidosis type IVB (MPS IVB). The phenotype of GM1 gangliosidosis constitutes a spectrum ranging from severe (infantile) to intermediate (late-infantile and juvenile) to mild (chronic/adult). Type I (infantile) GM1 gangliosidosis begins before age 12 months. Prenatal manifestations may include nonimmune hydrops fetalis, intrauterine growth restriction, and placental vacuolization; congenital dermal melanocytosis (Mongolian spots) may be observed. Macular cherry-red spot is detected on eye exam. Progressive central nervous system dysfunction leads to spasticity and rapid regression; blindness, deafness, decerebrate rigidity, seizures, feeding difficulties, and oral secretions are observed. Life expectancy is two to three years. Type II can be subdivided into the late-infantile (onset age 1-3 years) and juvenile (onset age 3-10 years) phenotypes. Central nervous system dysfunction manifests as progressive cognitive, motor, and speech decline as measured by psychometric testing. There may be mild corneal clouding, hepatosplenomegaly, and/or cardiomyopathy; the typical course is characterized by progressive neurologic decline, progressive skeletal disease in some individuals (including kyphosis and avascular necrosis of the femoral heads), and progressive feeding difficulties leading to aspiration risk. Type III begins in late childhood to the third decade with generalized dystonia leading to unsteady gait and speech disturbance followed by extrapyramidal signs including akinetic-rigid parkinsonism. Cardiomyopathy develops in some and skeletal involvement occurs in most. Intellectual impairment is common late in the disease with prognosis directly related to the degree of neurologic impairment. MPS IVB is characterized by skeletal dysplasia with specific findings of axial and appendicular dysostosis multiplex, short stature (below 15th centile in adults), kyphoscoliosis, coxa/genu valga, joint laxity, platyspondyly, and odontoid hypoplasia. First signs and symptoms may be apparent at birth. Bony involvement is progressive, with more than 84% of adults requiring ambulation aids; life span does not appear to be limited. Corneal clouding is detected in some individuals and cardiac valvular disease may develop.</Attribute>
                <XRef ID="NBK164500" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="6479" />
                <XRef ID="6479" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">24156116</ID>
                <ID Source="BookShelf">NBK164500</ID>
              </Citation>
              <XRef ID="354" DB="Orphanet" />
              <XRef ID="79255" DB="Orphanet" />
              <XRef ID="C0268271" DB="MedGen" />
              <XRef ID="MONDO:0009260" DB="MONDO" />
              <XRef Type="MIM" ID="230500" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="245" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="1390" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">GANGLIOSIDOSIS, GENERALIZED GM1, TYPE II</ElementValue>
                <XRef Type="MIM" ID="230600" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">GM1-GANGLIOSIDOSIS, TYPE II</ElementValue>
                <XRef Type="MIM" ID="230600" DB="OMIM" />
                <XRef Type="Allelic variant" ID="611458.0022" DB="OMIM" />
                <XRef Type="Allelic variant" ID="611458.0003" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Juvenile GM&gt;1&lt; gangliosidosis</ElementValue>
                <XRef ID="18756002" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gangliosidosis, generalized GM1, juvenile type</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gangliosidosis, Generalized GM1, Type 2</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">GM1 gangliosidosis type 2</ElementValue>
                <XRef ID="MONDO:0009261" DB="MONDO" />
                <XRef ID="79256" DB="Orphanet" />
              </Name>
              <AttributeSet>
                <Attribute Type="keyword">GLB1-Related Disorders</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="10126" />
                <XRef ID="10126" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">GLB1-related disorders comprise two phenotypically distinct lysosomal storage disorders: GM1 gangliosidosis and mucopolysaccharidosis type IVB (MPS IVB). The phenotype of GM1 gangliosidosis constitutes a spectrum ranging from severe (infantile) to intermediate (late-infantile and juvenile) to mild (chronic/adult). Type I (infantile) GM1 gangliosidosis begins before age 12 months. Prenatal manifestations may include nonimmune hydrops fetalis, intrauterine growth restriction, and placental vacuolization; congenital dermal melanocytosis (Mongolian spots) may be observed. Macular cherry-red spot is detected on eye exam. Progressive central nervous system dysfunction leads to spasticity and rapid regression; blindness, deafness, decerebrate rigidity, seizures, feeding difficulties, and oral secretions are observed. Life expectancy is two to three years. Type II can be subdivided into the late-infantile (onset age 1-3 years) and juvenile (onset age 3-10 years) phenotypes. Central nervous system dysfunction manifests as progressive cognitive, motor, and speech decline as measured by psychometric testing. There may be mild corneal clouding, hepatosplenomegaly, and/or cardiomyopathy; the typical course is characterized by progressive neurologic decline, progressive skeletal disease in some individuals (including kyphosis and avascular necrosis of the femoral heads), and progressive feeding difficulties leading to aspiration risk. Type III begins in late childhood to the third decade with generalized dystonia leading to unsteady gait and speech disturbance followed by extrapyramidal signs including akinetic-rigid parkinsonism. Cardiomyopathy develops in some and skeletal involvement occurs in most. Intellectual impairment is common late in the disease with prognosis directly related to the degree of neurologic impairment. MPS IVB is characterized by skeletal dysplasia with specific findings of axial and appendicular dysostosis multiplex, short stature (below 15th centile in adults), kyphoscoliosis, coxa/genu valga, joint laxity, platyspondyly, and odontoid hypoplasia. First signs and symptoms may be apparent at birth. Bony involvement is progressive, with more than 84% of adults requiring ambulation aids; life span does not appear to be limited. Corneal clouding is detected in some individuals and cardiac valvular disease may develop.</Attribute>
                <XRef ID="NBK164500" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">24156116</ID>
                <ID Source="BookShelf">NBK164500</ID>
              </Citation>
              <XRef ID="354" DB="Orphanet" />
              <XRef ID="79256" DB="Orphanet" />
              <XRef ID="C0268272" DB="MedGen" />
              <XRef ID="MONDO:0009261" DB="MONDO" />
              <XRef Type="MIM" ID="230600" DB="OMIM" />
              <Comment DataSource="NCBI curation" Type="public">REVIEWED: Set the orphanet value to preferred to avoid the annotation for the subscript</Comment>
            </Trait>
          </TraitSet>
          <TraitSet ID="246" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="1939" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">GANGLIOSIDOSIS, GENERALIZED GM1, ADULT TYPE</ElementValue>
                <XRef Type="MIM" ID="230650" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">GANGLIOSIDOSIS, GENERALIZED GM1, CHRONIC TYPE</ElementValue>
                <XRef Type="MIM" ID="230650" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">GANGLIOSIDOSIS, GENERALIZED GM1, TYPE III</ElementValue>
                <XRef Type="MIM" ID="230650" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">GM1-GANGLIOSIDOSIS, TYPE III</ElementValue>
                <XRef Type="MIM" ID="230650" DB="OMIM" />
                <XRef Type="Allelic variant" ID="611458.0004" DB="OMIM" />
                <XRef Type="Allelic variant" ID="611458.0014" DB="OMIM" />
                <XRef Type="Allelic variant" ID="611458.0008" DB="OMIM" />
                <XRef Type="Allelic variant" ID="611458.0013" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Beta-galactosidase deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Adult GM1 gangliosidosis</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Type 3 (adult) GM1 gangliosidosis</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">GM1 gangliosidosis type 3</ElementValue>
                <XRef ID="MONDO:0009262" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gangliosidosis, Generalized GM1, Type 3</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">GLB1-related disorders comprise two phenotypically distinct lysosomal storage disorders: GM1 gangliosidosis and mucopolysaccharidosis type IVB (MPS IVB). The phenotype of GM1 gangliosidosis constitutes a spectrum ranging from severe (infantile) to intermediate (late-infantile and juvenile) to mild (chronic/adult). Type I (infantile) GM1 gangliosidosis begins before age 12 months. Prenatal manifestations may include nonimmune hydrops fetalis, intrauterine growth restriction, and placental vacuolization; congenital dermal melanocytosis (Mongolian spots) may be observed. Macular cherry-red spot is detected on eye exam. Progressive central nervous system dysfunction leads to spasticity and rapid regression; blindness, deafness, decerebrate rigidity, seizures, feeding difficulties, and oral secretions are observed. Life expectancy is two to three years. Type II can be subdivided into the late-infantile (onset age 1-3 years) and juvenile (onset age 3-10 years) phenotypes. Central nervous system dysfunction manifests as progressive cognitive, motor, and speech decline as measured by psychometric testing. There may be mild corneal clouding, hepatosplenomegaly, and/or cardiomyopathy; the typical course is characterized by progressive neurologic decline, progressive skeletal disease in some individuals (including kyphosis and avascular necrosis of the femoral heads), and progressive feeding difficulties leading to aspiration risk. Type III begins in late childhood to the third decade with generalized dystonia leading to unsteady gait and speech disturbance followed by extrapyramidal signs including akinetic-rigid parkinsonism. Cardiomyopathy develops in some and skeletal involvement occurs in most. Intellectual impairment is common late in the disease with prognosis directly related to the degree of neurologic impairment. MPS IVB is characterized by skeletal dysplasia with specific findings of axial and appendicular dysostosis multiplex, short stature (below 15th centile in adults), kyphoscoliosis, coxa/genu valga, joint laxity, platyspondyly, and odontoid hypoplasia. First signs and symptoms may be apparent at birth. Bony involvement is progressive, with more than 84% of adults requiring ambulation aids; life span does not appear to be limited. Corneal clouding is detected in some individuals and cardiac valvular disease may develop.</Attribute>
                <XRef ID="NBK164500" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="2431" />
                <XRef ID="2431" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">24156116</ID>
                <ID Source="BookShelf">NBK164500</ID>
              </Citation>
              <XRef ID="79257" DB="Orphanet" />
              <XRef ID="C0268273" DB="MedGen" />
              <XRef ID="MONDO:0009262" DB="MONDO" />
              <XRef Type="MIM" ID="230650" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="9460" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="17556" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">not provided</ElementValue>
                <XRef ID="13DG0619" DB="Department Of Translational Genomics (developmental Genetics Section), King Faisal Specialist Hospital &amp; Research Centre" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">none provided</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">The term 'not provided' is registered in MedGen to support identification of submissions to ClinVar for which no condition was named when assessing the variant. 'not provided' differs from 'not specified', which is used when a variant is asserted to be benign, likely benign, or of uncertain significance for conditions that have not been specified.</Attribute>
              </AttributeSet>
              <XRef ID="C3661900" DB="MedGen" />
            </Trait>
          </TraitSet>
          <TraitSet ID="10013" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="7352" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">GM1 gangliosidosis</ElementValue>
                <XRef ID="MONDO:0018149" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Beta galactosidase 1 deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">GLB 1 deficiency</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="10891" />
                <XRef ID="10891" DB="Office of Rare Diseases" />
              </AttributeSet>
              <XRef ID="354" DB="Orphanet" />
              <XRef ID="C0085131" DB="MedGen" />
              <XRef ID="MONDO:0018149" DB="MONDO" />
            </Trait>
            <Trait ID="2965" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">MPS IVB</ElementValue>
                <XRef Type="MIM" ID="253010" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Morquio syndrome B</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Mucopolysaccharidosis type 4B</ElementValue>
                <XRef ID="MONDO:0009660" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Mucopolysaccharidosis Type IVB</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Mucopolysaccharidosis, MPS-IV-B</ElementValue>
                <XRef ID="Morquio+syndrome+B/4877" DB="Genetic Alliance" />
                <XRef ID="238044004" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Mucopolysaccharidosis type IVB (Morquio)</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">MPS 4B</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Mucopolysaccharidosis type IV B</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">MPS4B</ElementValue>
                <XRef Type="MIM" ID="253010" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">GLB1-related disorders comprise two phenotypically distinct lysosomal storage disorders: GM1 gangliosidosis and mucopolysaccharidosis type IVB (MPS IVB). The phenotype of GM1 gangliosidosis constitutes a spectrum ranging from severe (infantile) to intermediate (late-infantile and juvenile) to mild (chronic/adult). Type I (infantile) GM1 gangliosidosis begins before age 12 months. Prenatal manifestations may include nonimmune hydrops fetalis, intrauterine growth restriction, and placental vacuolization; congenital dermal melanocytosis (Mongolian spots) may be observed. Macular cherry-red spot is detected on eye exam. Progressive central nervous system dysfunction leads to spasticity and rapid regression; blindness, deafness, decerebrate rigidity, seizures, feeding difficulties, and oral secretions are observed. Life expectancy is two to three years. Type II can be subdivided into the late-infantile (onset age 1-3 years) and juvenile (onset age 3-10 years) phenotypes. Central nervous system dysfunction manifests as progressive cognitive, motor, and speech decline as measured by psychometric testing. There may be mild corneal clouding, hepatosplenomegaly, and/or cardiomyopathy; the typical course is characterized by progressive neurologic decline, progressive skeletal disease in some individuals (including kyphosis and avascular necrosis of the femoral heads), and progressive feeding difficulties leading to aspiration risk. Type III begins in late childhood to the third decade with generalized dystonia leading to unsteady gait and speech disturbance followed by extrapyramidal signs including akinetic-rigid parkinsonism. Cardiomyopathy develops in some and skeletal involvement occurs in most. Intellectual impairment is common late in the disease with prognosis directly related to the degree of neurologic impairment. MPS IVB is characterized by skeletal dysplasia with specific findings of axial and appendicular dysostosis multiplex, short stature (below 15th centile in adults), kyphoscoliosis, coxa/genu valga, joint laxity, platyspondyly, and odontoid hypoplasia. First signs and symptoms may be apparent at birth. Bony involvement is progressive, with more than 84% of adults requiring ambulation aids; life span does not appear to be limited. Corneal clouding is detected in some individuals and cardiac valvular disease may develop.</Attribute>
                <XRef ID="NBK164500" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="3786" />
                <XRef ID="3786" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">24156116</ID>
                <ID Source="BookShelf">NBK164500</ID>
              </Citation>
              <XRef ID="309310" DB="Orphanet" />
              <XRef ID="582" DB="Orphanet" />
              <XRef ID="C0086652" DB="MedGen" />
              <XRef ID="MONDO:0009660" DB="MONDO" />
              <XRef Type="MIM" ID="253010" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="1803006" SubmissionDate="2019-04-08" DateLastUpdated="2019-06-17" DateCreated="2019-06-17">
        <ClinVarSubmissionID localKey="NM_000404.3:c.1577dup|MedGen:CN169666" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000923441" DateUpdated="2019-06-17" DateCreated="2019-06-17" Type="SCV" Version="1" SubmitterName="Genomic Research Center, Shahid Beheshti University of Medical Sciences" OrgID="504864" OrganizationCategory="laboratory" OrgAbbreviation="GRC" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2019-01-01">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>inherited</Origin>
              <GeographicOrigin>Iran</GeographicOrigin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="1" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="VariantChromosomes" integerValue="2" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GLB1" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000404.3:c.1577dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">GLB1-Related Disorders</ElementValue>
            </Name>
            <XRef DB="MedGen" ID="CN169666" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>NGS_2019</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1832510" SubmissionDate="2024-02-15" DateLastUpdated="2024-02-28" DateCreated="2019-08-14">
        <ClinVarSubmissionID localKey="3547110|MedGen:C0086652;C0085131" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000938621" DateUpdated="2024-02-28" DateCreated="2019-08-14" Type="SCV" Version="3" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-12-30">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">18524657</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">10338095</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">15986423</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">16941474</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">17309651</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">25936995</ID>
          </Citation>
          <Comment>This sequence change creates a premature translational stop signal (p.Trp527Leufs*5) in the GLB1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in GLB1 are known to be pathogenic (PMID: 18524657). This variant is present in population databases (rs794729217, gnomAD 0.003%). This premature translational stop signal has been observed in individual(s) with GM1 gangliosidosis (PMID: 10338095, 15986423, 16941474, 17309651, 25936995). This variant is also known as c.1622_1627insG,1606_1611insG, c.1577 1578insG, or c.1572_1577insG. ClinVar contains an entry for this variant (Variation ID: 202191). For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GLB1" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000003.11:g.33055704_33055705insC</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease" multipleConditionExplanation="Uncertain">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0086652" Type="CUI" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0085131" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12507860</SubmissionName>
          <SubmissionName>SUB14224806</SubmissionName>
          <SubmissionName>SUB5371970</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2469610" SubmissionDate="2024-07-04" DateLastUpdated="2024-07-15" DateCreated="2020-05-12">
        <ClinVarSubmissionID localKey="102049|MedGen:CN517202" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001248011" DateUpdated="2024-07-15" DateCreated="2020-05-12" Type="SCV" Version="23" SubmitterName="CeGaT Center for Human Genetics Tuebingen" OrgID="505870" OrganizationCategory="laboratory" OrgAbbreviation="CHGT" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2018-06-01">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">CeGaT Center For Human Genetics Tuebingen Variant Classification Criteria Version 2</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/api/2.0/files/0ynenhfo/cegat_center_for_human_genetics_tuebingen_-_variant_classification_criteria_-_version_2.pdf/?format=attachment</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="3" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GLB1" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <SequenceLocation Assembly="GRCh37" Chr="3" alternateAllele="GC" referenceAllele="G" start="33055704" stop="33055704" variantLength="1" />
          </Location>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="CN517202" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>2021-07</SubmissionName>
          <SubmissionName>2021-10</SubmissionName>
          <SubmissionName>2022-01</SubmissionName>
          <SubmissionName>2022-01-corrected</SubmissionName>
          <SubmissionName>2022-04</SubmissionName>
          <SubmissionName>2022-07</SubmissionName>
          <SubmissionName>2022-08</SubmissionName>
          <SubmissionName>2022-10.3</SubmissionName>
          <SubmissionName>2023-01</SubmissionName>
          <SubmissionName>2023-04</SubmissionName>
          <SubmissionName>2023-09-add-ACMG-details</SubmissionName>
          <SubmissionName>2023-10</SubmissionName>
          <SubmissionName>2024-04</SubmissionName>
          <SubmissionName>SUB13641132</SubmissionName>
          <SubmissionName>SUB13985080</SubmissionName>
          <SubmissionName>SUB14102099</SubmissionName>
          <SubmissionName>SUB14290090</SubmissionName>
          <SubmissionName>SUB14426581</SubmissionName>
          <SubmissionName>SUB14513473</SubmissionName>
          <SubmissionName>SUB14584463</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1457114" SubmissionDate="2019-01-29" DateLastUpdated="2018-05-21" DateCreated="2018-05-21">
        <ClinVarSubmissionID localKey="GDX:24269|Not Provided" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000748400" DateUpdated="2018-05-21" DateCreated="2018-05-21" Type="SCV" Version="3" SubmitterName="GeneDx" OrgID="26957" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2018-04-03">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>The c.1577dupG variant in the GLB1 gene has been reported previously using alternate nomenclature (1622-1627insG) in association with autosomal recessive GM1-gangliosidosis type I (Silva et al., 1999). This variant is common in individuals from Brazil, having been identified in 42.5% of alleles from affected individuals in one study (Silva et al., 1999). The c.1577dupG variant causes a frameshift starting with codon Tryptophan 527, changes this amino acid to a Leucine residue, and creates a premature Stop codon at position 5 of the new reading frame, denoted p.Trp527LeufsX5. This variant is predicted to cause loss of normal protein function either through protein truncation or nonsense-mediated mRNA decay. The c.1577dupG variant is not observed at a significant frequency in large population cohorts (Lek et al., 2016). We interpret c.1577dupG as a pathogenic variant.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">GeneDx Variant Classification (06012015)</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/dhtz9flo/genedx_interprules_final_061215.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GLB1" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <SequenceLocation Assembly="GRCh37" Chr="3" alternateAllele="CC" referenceAllele="C" start="33055704" stop="33055705" variantLength="2" />
          </Location>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000404.2:c.1577dupG</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Not Provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB5098196</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2242159" SubmissionDate="2019-10-22" DateLastUpdated="2020-01-11" DateCreated="2020-01-11">
        <ClinVarSubmissionID localKey="NC_000003.11:g.33055704_33055705insC|OMIM:230600" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001136360" DateUpdated="2020-01-11" DateCreated="2020-01-11" Type="SCV" Version="1" SubmitterName="Mendelics" OrgID="500035" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2019-05-28">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Mendelics Assertion Criteria 2017</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/chhjzatu/mendelics_assertion_criteria_2017.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GLB1" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000003.11:g.33055704_33055705insC</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="230600" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>MENDELICS_CLINVAR_020</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2838485" SubmissionDate="2020-10-06" DateLastUpdated="2020-10-08" DateCreated="2020-10-08">
        <ClinVarSubmissionID localKey="NM_000404.3:c.1577dupG|MedGen:C0085131" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001437247" DateUpdated="2020-10-08" DateCreated="2020-10-08" Type="SCV" Version="1" SubmitterName="Women's Health and Genetics/Laboratory Corporation of America, LabCorp" OrgID="500026" OrganizationCategory="laboratory" OrgAbbreviation="WHG-LC" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2020-09-17">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">10338095</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">31761138</ID>
          </Citation>
          <Comment>Variant summary: GLB1 c.1577dupG (p.Trp527LeufsX5) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. The variant allele was found at a frequency of 8.1e-06 in 247798 control chromosomes (gnomAD). c.1577dupG has been reported in the literature, in the compound heterozygous and homozygous state, in multiple individuals affected with GM1 Gangliosidosis (e.g. Silva_1999, Arash-Kaps_2019). These data indicate that the variant is very likely to be associated with disease. Five ClinVar submitters (evaluation after 2014) cite the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">LabCorp Variant Classification Summary - May 2015</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/rtxspsnt/labcorp_variant_classification_method_-_may_2015.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GLB1" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000404.3:c.1577dupG</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">GM1 gangliosidosis</ElementValue>
            </Name>
            <XRef DB="MedGen" ID="C0085131" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB8280815</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="3562294" SubmissionDate="2021-09-01" DateLastUpdated="2022-10-01" DateCreated="2021-09-08">
        <ClinVarSubmissionID localKey="NM_000404.4:c.1577dupG|OMIM:230500" submittedAssembly="not applicable" />
        <ClinVarAccession Accession="SCV001821205" DateUpdated="2022-10-01" DateCreated="2021-09-08" Type="SCV" Version="2" SubmitterName="GeneReviews" OrgID="500062" OrganizationCategory="resource" OrgAbbreviation="GeneReviews" />
        <RecordStatus>current</RecordStatus>
        <Classification>
          <ReviewStatus>no classification provided</ReviewStatus>
          <GermlineClassification>not provided</GermlineClassification>
          <Citation>
            <ID Source="PubMed">21637542</ID>
          </Citation>
          <Comment>High prevalence in Brazilian population; associated with GM1 infantile form</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name>1622_1627insG</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000404.4:c.1577dupG</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0268271" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB10303272</SubmissionName>
          <SubmissionName>SUB11808016</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="7113715" SubmissionDate="2023-03-01" DateLastUpdated="2023-03-04" DateCreated="2023-03-04">
        <ClinVarSubmissionID localKey="045b98bbcdec167db76a9a98824be9c2" localKeyIsSubmitted="1" submittedAssembly="GRCh38" />
        <ClinVarAccession Accession="SCV003807647" DateUpdated="2023-03-04" DateCreated="2023-03-04" Type="SCV" Version="1" SubmitterName="Laboratorio de Genetica e Diagnostico Molecular, Hospital Israelita Albert Einstein" OrgID="508506" OrganizationCategory="laboratory" OrgAbbreviation="LABO-HIAE" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-10-17">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>ACMG classification criteria: PVS1 very strong, PM2 moderated, PM3 very strong</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <GeographicOrigin>Brazil</GeographicOrigin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
              <NumberTested>1</NumberTested>
            </Sample>
            <Method>
              <Description>Paired-end whole-genome sequencing</Description>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="1" />
            </ObservedData>
            <TraitSet Type="Finding">
              <Trait ClinicalFeaturesAffectedStatus="present" Type="Finding">
                <XRef DB="HP" ID="HP:0002650" />
              </Trait>
              <Trait ClinicalFeaturesAffectedStatus="present" Type="Finding">
                <XRef DB="HP" ID="HP:0001276" />
              </Trait>
              <Trait ClinicalFeaturesAffectedStatus="present" Type="Finding">
                <XRef DB="HP" ID="HP:0007325" />
              </Trait>
              <Trait ClinicalFeaturesAffectedStatus="present" Type="Finding">
                <XRef DB="HP" ID="HP:0001371" />
              </Trait>
            </TraitSet>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GLB1" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000404.4:c.1577dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="230650" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12925816</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="2242159" TraitType="Disease" MappingType="XRef" MappingValue="230600" MappingRef="OMIM">
        <MedGen CUI="C0268272" Name="GM1 gangliosidosis type 2" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1832510" TraitType="Disease" MappingType="XRef" MappingValue="C0085131" MappingRef="MedGen">
        <MedGen CUI="C0085131" Name="GM1 gangliosidosis" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7113715" TraitType="Finding" MappingType="XRef" MappingValue="HP:0001276" MappingRef="HP">
        <MedGen CUI="C0026826" Name="Hypertonia" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7113715" TraitType="Finding" MappingType="XRef" MappingValue="HP:0002650" MappingRef="HP">
        <MedGen CUI="C0036439" Name="Scoliosis" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2469610" TraitType="Disease" MappingType="XRef" MappingValue="CN517202" MappingRef="MedGen">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7113715" TraitType="Finding" MappingType="XRef" MappingValue="HP:0007325" MappingRef="HP">
        <MedGen CUI="C1848954" Name="Generalized dystonia" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3562294" TraitType="Disease" MappingType="XRef" MappingValue="C0268271" MappingRef="MedGen">
        <MedGen CUI="C0268271" Name="Infantile GM1 gangliosidosis" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1457114" TraitType="Disease" MappingType="Name" MappingValue="Not Provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1803006" TraitType="Disease" MappingType="Name" MappingValue="GLB1-Related Disorders" MappingRef="Preferred">
        <MedGen CUI="CN377807" Name="GLB1-related disorder" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7113715" TraitType="Finding" MappingType="XRef" MappingValue="HP:0001371" MappingRef="HP">
        <MedGen CUI="C0333068" Name="Flexion contracture" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2838485" TraitType="Disease" MappingType="Name" MappingValue="GM1 gangliosidosis" MappingRef="Preferred">
        <MedGen CUI="C0085131" Name="GM1 gangliosidosis" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7113715" TraitType="Disease" MappingType="XRef" MappingValue="230650" MappingRef="OMIM">
        <MedGen CUI="C0268273" Name="GM1 gangliosidosis type 3" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1832510" TraitType="Disease" MappingType="XRef" MappingValue="C0086652" MappingRef="MedGen">
        <MedGen CUI="C0086652" Name="Mucopolysaccharidosis, MPS-IV-B" />
      </TraitMapping>
    </TraitMappingList>
    <DeletedSCVList>
      <SCV>
        <Accession Version="1" DateDeleted="2024-04-05">SCV000236568</Accession>
        <Description>Duplicate entry</Description>
      </SCV>
    </DeletedSCVList>
  </ClassifiedRecord>
</VariationArchive>

